EVCM

ANALYST NOTE: EVCM (EverCommerce Inc.) Date: 2026-06-13 Current Price: $8.95

1. Structural Readiness

• Conservative Entry: — (Not yet triggered; requires a confirmed breakout above the defined resistance level)
• Aggressive/Pre-Breakout Entry: — (Not actionable on its own; requires confirmation)
• Breakout Level: — (Not yet fired; price is currently consolidating)
• Current Price: $8.95
• Extension: — (No extension data provided relative to a breakout level)
• ATR Context: Current ATR is 7.3% (Very High). This indicates elevated volatility, which impacts position sizing but does not alter the structural state of the coil.

2. Thesis Layer

• Thesis Classification: TACTICAL / SETUP-LED
• Secular Exposure: No named secular thesis is attached to this name as of 2026-06-13.
• Judgment Framework: The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the underlying business fundamentals (revenue growth, margin expansion, and AI monetization). Do not invent a macro thesis; the conviction rests on the company's ability to execute its stated operational improvements and the market's reaction to the technical breakout.

3. Business Overview

EverCommerce Inc. operates as a SaaS provider delivering comprehensive software solutions to service-oriented small and medium-sized businesses (SMBs). The company serves over 745,000 customers globally across three core verticals:

• EverPro: Home and field services (e.g., construction, maintenance).
• EverHealth: Medical practices and health services.
• EverWell: Wellness and service providers (e.g., salons, fitness).

Business Model & Evidence:

• Revenue & Growth: As of the year ended December 31, 2025, revenue from continuing operations reached $588.9 million, representing a 4.8% year-over-year growth from 2024 and a 7.1% CAGR from 2022 to 2025 (Evidence E16).
• Guidance (Management Expectations): In the Q2 2026 earnings transcript (May 7, 2026), management reiterated full-year 2026 guidance: Revenue of $612 million to $632 million and Adjusted EBITDA of $183 million to $191 million (Evidence E2). For Q2 2026 specifically, they expect revenue of $150.5M–$153.5M and Adjusted EBITDA of $41M–$43M (Evidence E1).
• Monetization & AI: Management states they are transitioning from AI investment to the monetization of targeted investments (Evidence E4). This includes the acquisition of ZyraTalk (an AI-powered customer engagement solution) in September 2025 for ~$36.0M, which is being applied to the EverPro vertical and planned for expansion (Evidence E13, E14).
• Cross-Selling: Multi-solution adoption is accelerating. As of Q1 2026, approximately 131,000 customers were actively using more than one solution, reflecting 32% year-over-year growth (Evidence E6).
• Payment Volume: Transaction Processing Volume (TPV) in top solutions grew 19.8% year-over-year, now representing 35% of total TPV (Evidence E8).
• Market Context: The company targets a Total Addressable Market (TAM) estimated at $1.6 trillion globally, with significant opportunities in Home Services ($69B), Health Services ($115B), and Wellness ($22B) in North America (Evidence E21).

4. Archetype and Conviction

• Archetype: Deep Value Recovery
• Fit Analysis: The name fits the "Deep Value Recovery" archetype due to its transition from a growth-at-all-costs phase to a disciplined profitability phase.
• Margin Inflector: Adjusted EBITDA grew from $164.4M (2024) to $180.5M (2025), and management expects further expansion to $183M–$191M for 2026 (Evidence E17, E2).
• Pricing Power: Management explicitly notes that pricing actions will have a "larger impact in the back half" of 2026, suggesting a structural shift in revenue quality (Evidence E3).
• Valuation Context: Forward consensus EPS for FY1 is $0.706 and FY2 is $0.758 (Evidence E31). At a price of $8.95, the stock trades at approximately 12.7x FY1 forward EPS, which aligns with a value/recovery narrative rather than a high-growth multiple.
• Conviction Stack:
• Thesis Strength: Moderate. It is a tactical setup without a broad secular tailwind, relying on internal execution.
• Evidence Quality: High. Recent earnings (May 2026) and filings (March 2026) provide clear, quantitative guidance and operational metrics.
• Structural Quality: The "Very High" ATR (7.3%) suggests the stock is volatile, which is common in recovery names but requires careful sizing. The forming coil indicates the market is digesting the recent guidance before a potential move.
• Rerating Potential: Dependent on the successful monetization of AI (ZyraTalk) and the acceleration of multi-solution adoption.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen: A confirmed breakout above the resistance level (triggering the "Confirmed-Active" state) accompanied by volume, validating the "Deep Value Recovery" thesis. Continued acceleration in multi-solution adoption (>32% growth) would further strengthen the case.
• Gaps in Evidence:
• Breakout Confirmation: No data exists on the specific resistance level or the volume profile required for a confirmed breakout.
• AI Revenue Contribution: While ZyraTalk is acquired, the specific revenue contribution from this AI initiative in Q2 2026 is not quantified in the provided evidence, only the strategic intent.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management reiterated full-year 2026 EBITDA guidance of $183M-$191M; Multi-solution adoption grew 32% YoY to 131,000 customers; Acquisition of ZyraTalk signals active AI monetization strategy. Key risks: Very high ATR (7.3%) indicates elevated volatility and potential for sharp downside if support fails; No named secular thesis creates reliance on pure setup execution; Pricing action impact timing is uncertain. Sizing hint: Reduce position size relative to historical norms due to very high volatility and unconfirmed breakout status. Expected path: Management expects pricing actions to drive back-half revenue; AI monetization to begin contributing to top-line growth; stock likely to consolidate until breakout confirmation. Expected horizon: 3 to 6 months for structural confirmation or invalidation.